Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock
NASDAQ · SGMT
9.25
Fundamentals
Market cap
$574.35M
Price / Earnings ratio
-12.0x
Price / Sales ratio
N/A
Price / Book ratio
2.2x
Return on assets
-36.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
NeutralSGMTAugust 17, 2026
MarketBeatNeutral
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
SGMT

Zacks Investment Research
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
NeutralSGMTJune 4, 2026
Zacks Investment ResearchNeutral
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
SGMT

Zacks Investment Research
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
NeutralSGMTMay 21, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
SGMT

Zacks Investment Research
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
NeutralSGMTMay 5, 2026
Zacks Investment ResearchNeutral
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
SGMT
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell1
Neutral0
Buy5
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
140M92M46M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-51.0M
Net incomeEarnings
No data available
% positive news of 6 articles
published over the past 14 days
Latest news

MarketBeat
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
NeutralSGMTAugust 17, 2026
MarketBeatNeutral
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
SGMT

Zacks Investment Research
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
NeutralSGMTJune 4, 2026
Zacks Investment ResearchNeutral
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
SGMT

Zacks Investment Research
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
NeutralSGMTMay 21, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
SGMT

Zacks Investment Research
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
NeutralSGMTMay 5, 2026
Zacks Investment ResearchNeutral
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
SGMT

Zacks Investment Research
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
NeutralSGMTMay 5, 2026
Zacks Investment ResearchNeutral
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
SGMT

Stocktwits
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?
NeutralSGMTApril 27, 2026
StocktwitsNeutral
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?
SGMT
About Sagimet Biosciences Inc. Series A Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees16
CEOMr. David A. Happel
IPO DateJul 14, 2023
HeadquartersSan Mateo, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David A. Happel | CEO, President & Director | 1962 |
| Ms. Elizabeth Rozek Esq., J.D. | Chief Legal & Administrative Officer | 1972 |
| Mr. Urs Greber Ph.D. | Co-Founder | — |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder | — |
| Mr. Thierry Chauche | CFO & Principal Accounting Officer | 1976 |
| Dr. Marie O'Farrell Ph.D. | Chief Scientific Officer | — |
| Mr. Robert D'Urso | Senior Vice President of New Products | — |
| Dr. Andreas Grauer M.D. | Chief Medical Officer | 1961 |
Fundamentals
Valuation
Market cap$574.35M
Price-to-sales ratioN/A
Price-to-book value2.21
Price-earnings ratio-12.00
Return on Equity-38.00%
Return on SalesN/A
Return on Assets-36.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.29
Income Statement
Average volume1,092,493
EBITDA$-43.36M
1 year high (52w)$11.45
1 year low (52w)$4.50
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
6 Wall Street Analyst Ratings
BUY
83% Buy
0% Hold
17% Sell
Target price
$24.95
Est return
170.04%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +0.0 | -24.5 | -26.7 | -52.0 | +7.6 | +43.0 | ||||||
| 2024 | +77.9 | -38.7 | -10.0 | -25.4 | +29.7 | -34.0 | +6.3 | -11.5 | -6.4 | +65.1 | +6.8 | -16.0 |
| 2025 | -2.0 | -20.2 | -5.5 | +33.7 | -9.7 | +118.3 | +8.2 | -9.0 | -6.8 | +22.1 | -10.4 | -12.9 |
| 2026 | -5.3 | -8.3 | -8.6 | +53.2 | -4.2 | +7.5 | -4.7 | +43.5 | -12.0 |



